BIOT Appointed Representative for IN01 Cancer Immunotherapy
Consumer Goods
Strategic Partnership
Merger:
Jul 24, 2026
Industry:
PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS
Show Chart?
Load external content from TradingView!
*You can change or withdraw your consent at any time in the footer under Cookies.
BIOT Named Authorized Representative for IN01 Cancer Immunotherapy in Japan and China
NEW YORK and TOKYO, September 30, 2026 - INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC. (Nasdaq: BIOT) announced that CelSiege Biosciences Inc. has appointed BIOT on a non-exclusive basis as its authorized introduction and business development representative in Japan and the People's Republic of China for the IN01 clinical-stage cancer immunotherapy program.
... Read on — Members only
About INSTINCT BIO TECHNICAL CO HOLDINGS INC.
Instinct Bio is a biotechnology company focused on regenerative medicine, longevity-related technologies and advanced therapeutic platforms. The Company is committed to developing innovative solutions intended to address unmet medical needs and support long-term human health outcomes.
For more information, please visit the Company’s website at https://instinct-biot.com/
More BIOT News
Consumer Goods
Daily overview of upcoming SPAC and IPO events – from initial announcement to definitive agreement and public listing.
Discover last week’s SPAC and IPO highlights, key trends, and market updates. Stay informed with SpacStar.